ArticleAdvances in radiation oncology2026
Preoperative Single-Fraction Versus Fractionated Stereotactic Radiation Therapy: A Single-Institutional Analysis of 299 Resected Metastases.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The treatment standard for patients with large or symptomatic brain metastases and limited intracranial disease is surgical resection followed by postoperative stereotactic radiosurgery (SRS). Preoperative SRS may lead to a reduced incidence of radiation necrosis (RN), local failure (LF), and nodular meningeal disease (nMD). Fractionated treatments may reduce the incidence of LF and nMD. We hypothesize that preoperative fractionated stereotactic radiation therapy will reduce the incidence rate of RN, LD, and nMD compared to patients receiving preoperative SRS. Methods and Materials: Patients who had surgical resection and preoperative radiation to at least one brain metastasis at a single institution were retrospectively analyzed. Outcomes were evaluated on a per-lesion basis. The primary outcome was a composite endpoint defined by (1) LF; (2) nMD; and/or (3) grade 2 or higher (symptomatic) RN. Results: 299 resected brain metastases from 260 patients were eligible for analysis. Two hundred thirty-five metastases received fractionated stereotactic radiation therapy (FSRT) and 64 received SRS. Thirty-eight patients had multiple metastases resected preoperatively. Overall, 4 (6.3%) SRS and 6 (2.6%) FSRT metastases experienced LF. Four (6.2%) SRS and 21 (9.1%) FSRT metastases experienced grade 2 or higher RN. Three (4.7%) SRS and 11 (4.7%) FSRT metastases were diagnosed with leptomeningeal disease. Additionally, 3 (4.6%) and 0 (0%) of SRS, and 8 (3.4%) and 4 (1.7%) of FSRT patients experienced classical or nodular meningeal disease, respectively. Eleven percent and 12% of SRS and FSRT metastases experienced the composite endpoint. Conclusions: In our study, preoperative SRS and FSRT both appear to be safe and effective options to treat resectable brain metastases. It is important to prospectively compare preoperative SRS and FSRT in matched cohorts to assess any differences in treatment efficacy and toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.